GlassScriptPhysician profile
Alexis Hess
NPI 1750964011
$6,403.51
in general payments reported to CMS, 2019-2025
33 companies · $308 in 2025
The $308 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,735 · 2022: $2,081 · 2023: $1,797 · 2024: $483 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,485 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,484.97 |
| Education | $102.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $861.74 | 2021-2024 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $797.30 | 2021-2024 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $746.86 | 2021-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $684.35 | 2021-2024 | Acthar, Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $628.74 | 2021-2024 | |
| Aurinia Pharma U.S., INC. | $532.14 | 2021-2023 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $403.07 | 2021-2025 | Jynarque, Rexulti, Abilify Asimtufii |
| Pharmacosmos Therapeutics INC. | $230.60 | 2021-2023 | Monoferric |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $143.57 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $134.24 | 2021 | |
| Fresenius USA Marketing, INC. | $131.01 | 2021-2024 | Velphoro |
| Amgen INC. | $125.61 | 2022-2023 | Tavneos |
| Ardelyx, INC. | $124.83 | 2024 | Xphozah 30 Mg, Ibsrela |
| Novo Nordisk INC | $117.17 | 2021-2025 | Wegovy |
| Opko Pharmaceuticals, LLC | $101.40 | 2021-2023 | Rayaldee |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $96.75 | 2022 | |
| Sanofi-Aventis U.S. LLC | $74.56 | 2024-2025 | |
| Ultragenyx Pharmaceutical INC. | $66.91 | 2021-2022 | |
| Glaxosmithkline, LLC. | $53.67 | 2022-2023 | Benlysta, Jesduvroq |
| Takeda Pharmaceuticals U.S.A., INC. | $50.00 | 2021-2023 | Gattex |
| Vanda Pharmaceuticals INC. | $33.74 | 2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.08 | 2025 | Caplyta |
| Ani Pharmaceuticals, INC. | $28.83 | 2023 | Purified Cortrophin Gel |
| Galderma Laboratories, L.P. | $26.59 | 2025 | |
| Cleerly, INC. | $24.35 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Aimmune Therapeutics, INC. | $22.34 | 2025 | Zenpep |
| Exact Sciences Corporation | $22.13 | 2025 | Cologuard Collection Kit |
| Pfizer INC. | $19.78 | 2025 | |
| Nevro Corp. | $18.59 | 2024 | Senza |
| Xeris Pharmaceuticals, INC. | $18.31 | 2023 | Keveyis |
| Leadiant Biosciences, INC. | $18.00 | 2022 | |
| Genzyme Corporation | $17.83 | 2022 | |
| Travere Therapeutics, INC. | $16.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexis Hess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.